









## Humber Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on October 2024

### Classification of products:

Status	Description
 <b>GREEN</b>	Medicines suitable for routine use within primary care and Secondary care. May be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies
 <b>AMB 1</b>	Specialist recommendation: These medicines are considered suitable for GP prescribing following specialist recommendation or via an APC approved prescribing guideline.
 <b>AMB 2</b>	Specialist initiation: These medicines are considered suitable for GP prescribing following specialist initiation, including titration of dose and assessment of efficacy. These medicines may also have an APC approved guideline to aid GPs in further prescribing.
 <b>AMB SCP</b>	AMBER SHARE CARE PROTOCOL- Specialist initiation with ongoing monitoring: Medicines that must be initiated by a specialist, and which require significant monitoring on an ongoing basis. Full agreement to share the care of each specific patient must be reached under the shared care protocol which must be provided to the GP. If a commissioned shared care is not available in CCG/place then these drugs must be treated as red drug (hospital only).
 <b>RED</b>	Red-Hospital initiation and continuation only
 <b>GREY</b>	GREY- NON FORMULARY (As agreed by Area Prescribing Committee)
 <b>PURPLE</b>	To be supplied from the appropriate commissioned provider.
 <b>NR</b>	Not routinely commissioned

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meetings</b>				
Nil this month				
<b>2) New Requests</b>				
Nil this month				
<b>3) New formulations &amp; extensions to use</b>				
Nil this month				
<b>4) Products considered by NICE</b>				

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<a href="#">TA991: Abaloparatide for treating osteoporosis after menopause</a>	RED			The formulary will reflect the TAG – ICS is the responsible commissioner
<a href="#">TA996: Linzagolix for treating moderate to severe symptoms of uterine fibroids</a>	RED			The formulary will reflect the TAG – ICS is the responsible commissioner. NHSE is the responsible commissioner for 16-17 years.
<a href="#">TA998: Risankizumab for treating moderately to severely active ulcerative colitis</a>	RED			The formulary will reflect the TAG – ICS is the responsible commissioner.
<a href="#">TA993: Burosumab for treating X-linked hypophosphataemia in adults</a>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<a href="#">TA997: Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma</a>	RED			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>5) Appeals against earlier decisions by the APC</b>				
<b>Nil this month</b>				
<b>6) Miscellaneous formulary decisions by the APC</b>				
<b>Nil this month</b>				

The following guidelines and pathways were presented to and approved at the October 2024 meeting of the APC:

- Humber Amber 1 guidance topical testosterone for management of low libido in menopause and post menopause
- CHCP Wound Management formulary (Hull/ERY)
- Opioid conversion chart

The following Drug information leaflets were presented to and approved at the October 2024 meeting of the APC:

- Nil this month

The following shared care guidelines were presented to and approved at the October 2024 meeting of the APC:

- Melatonin – Hull/ERY
- Mycophenolate – APC wide
- Methotrexate – APC wide
- Lithium – Navigo (NEL)

Other documents presented to and approved at the October 2024 meeting of the APC:

- Humber APC approved chapter 15